A new research paper was published by Aging (Aging-US) on January 8, 2025, in Volume 17, Issue 1, titled “Senolytic agent ABT-263 mitigates low- and high-LET radiation-induced gastrointestinal cancer ...

Our results offer 'proof of concept' for the future use of a pharmaceutical senolytic strategy to reduce the risk of ...

A new research paper was published by Aging (Aging-US) on January 8, 2025, in Volume 17, Issue 1, titled "Senolytic agent ABT-263 mitigates low- and high-LET radiation-induced gastrointestinal cancer ...

The Joint Clinical Research Centre (JCRC) at Lubowa in partnership with Asea BioTherapeutics (ABT) today successfully treated their first client with cutting-edge stem cell therapy, marking a historic ...

Uganda has treated its first patient using advanced stem cell therapy, marking a ground-breaking milestone in East Africa's medical history.Stem cell therapy, also known as regenerative medicine, uses ...

StockNews.com upgraded shares of Abbott Laboratories (NYSE:ABT – Free Report) from a buy rating to a strong-buy rating in a ...

Abbott Laboratories (NYSE:ABT – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” ...

Ugandans with chronic diseases who had taken long without being treated or had lost hope of getting the next lease of life can afford a smile following the launch of stem cell therapy.The Joint ...

The problem that really needs fixing is not the public employees but the private contractors—and Elon Musk is one of them.

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

ABT's financials remain exceptionally vibrant ... women's health, and pain management therapy areas. The company's Nutrition segment reported $2.13 billion in net sales during the fourth quarter ...